Patents Examined by Kevin Hill
-
Patent number: 9315559Abstract: Provided are methods for activating an antigen-presenting cell and eliciting an immune response by inducing an inducible pattern recognition receptor adapter, or adapter fragment, and CD40 activity. Also provided are nucleic acid compositions comprising sequences coding for chimeric proteins that include an inducible CD40 peptide and an inducible pattern recognition receptor adapter or adapter fragment.Type: GrantFiled: February 8, 2013Date of Patent: April 19, 2016Assignee: BAYLOR COLLEGE OF MEDICINEInventors: David Spencer, Priyadharshini Narayanan
-
Patent number: 9314529Abstract: An excellent nucleic acid delivery composition is provided which has reduced cytotoxicity and improved nucleic acid introduction efficiency and gene expression efficiency. The composition comprises: a block copolymer having an uncharged hydrophilic polymer segment and a cationic polymer segment; a cationic polymer; and a nucleic acid, wherein the mol percentage (B/H ratio) of the cationic groups of the block copolymer to the total cationic groups of the block copolymer and the cationic polymer is between 25% and 90%.Type: GrantFiled: July 11, 2011Date of Patent: April 19, 2016Assignee: The University of TokyoInventors: Kazunori Kataoka, Takehiko Ishii, Kensuke Osada, Qixian Chen, Keiji Itaka, Satoshi Uchida
-
Patent number: 9303080Abstract: The present invention provides for nucleic acids improved for the expression of interleukin-15 (IL-15) in mammalian cells. The invention further provides for methods of expressing IL-15 in mammalian cells by transfecting the cell with a nucleic acid sequence comprising a codon optimized IL-15 sequence. The present invention further provides expression vectors, and IL-15 and IL 15 receptor alpha combinations (nucleic acid and protein) that increase IL-15 stability and potency in vitro and in vivo. The present methods are useful for the increased bioavailability and biological effects of IL-15 after DNA, RNA or protein administration in a subject (e.g. a mammal, a human).Type: GrantFiled: January 12, 2007Date of Patent: April 5, 2016Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, National Institutes of HealthInventors: Barbara K. Felber, George N. Pavlakis
-
Patent number: 9284562Abstract: Described herein are novel biological circuit chemotactic converter that utilize modular components, such as genetic toggle switches and single invertase memory modules (SIMMs), for detecting and converting external inputs, such as chemoattractants, into outputs that allow for autonomous chemotaxis in cellular systems. Flexibility in these biological circuit chemotactic converter is provided by combining individual modular components, i.e., SIMMs and genetic toggle switches, together. These biological converter switches can be combined in a variety of network topologies to create network systems that regulate chemotactic responses based on the combination and nature of input signals received.Type: GrantFiled: November 30, 2010Date of Patent: March 15, 2016Assignees: Trustees of Boston University, Massachusetts Institute of TechnologyInventors: James J. Collins, Timothy Kuan-Ta Lu
-
Patent number: 9283184Abstract: The invention provides compositions and methods for delivering agents to localized regions, tissues, or organs in vivo by conjugating agent-loaded nanoparticles to cells having homing capability. The agents may be therapeutic or diagnostic agents such as cancer chemotherapeutic agents and imaging agents respectively.Type: GrantFiled: November 24, 2009Date of Patent: March 15, 2016Assignee: Massachusetts Institute of TechnologyInventors: Darrell J. Irvine, Matthias Stephan, Jaehyun Moon, Anna Bershteyn
-
Patent number: 9273310Abstract: Compositions and methods are disclosed herein for cloning a donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cell. Methods disclosed herein can be used to alter donor genomes from intractable donor cells in more tractable host cells.Type: GrantFiled: March 5, 2010Date of Patent: March 1, 2016Assignee: Synthetic Genomics, Inc.Inventors: Gwynedd A. Benders, John I. Glass, Clyde A. Hutchison, III, Carole Lartigue, Sanjay Vashee, Mikkel A. Algire, Hamilton O. Smith, Charles E. Merryman, Vladimir N. Noskov, Ray-Yuan Chuang, Daniel G. Gibson, J. Craig Venter
-
Patent number: 9267132Abstract: Compositions and methods are disclosed herein for cloning a synthetic or a semi-synthetic donor genome in a heterologous host cell. In one embodiment, the donor genome can be further modified within a host cell. Modified or unmodified genomes can be further isolated from the host cell and transferred to a recipient cell. Methods disclosed herein can be used to alter donor genomes from intractable donor cells in more tractable host cells.Type: GrantFiled: May 19, 2010Date of Patent: February 23, 2016Assignee: Synthetic Genomics, Inc.Inventors: Gwynedd A. Benders, John I. Glass, Clyde A. Hutchison, Carole Lartigue, Sanjay Vashee, Mikkel A. Algire, Hamilton O. Smith, Charles E. Merryman, Vladimir N. Noskov, Ray-Yuan Chuang, Daniel G. Gibson, J. Craig Venter
-
Patent number: 9248169Abstract: No effective vaccine exists for the devastating parasitic disease of Schistosomiasis. The present invention focuses on Sm-p80, a functionally important antigen of Schistosoma mansoni that plays a pivotal role in the schistosome immune evasion process. When used in a novel vaccine formulation, Sm-p80 demonstrates consistent immunogenicity, protective potential, and antifecundity effects. Two novel DNA constructs were made for immunization purposes. Sm-p80 coding sequence was cloned into VR 1020. Additionally, Sm-p80 coding sequence was cloned into pcDNA3.1 with flanking CpG motifs on each end of the Sm-p80 sequence. When used in different vaccine formulations, both of the constructs demonstrate the superior antifecundity and anti-worm effects of Sm-p80, which has great potential as an important vaccine candidate for the reduction of the morbidity associated with schistosome infection.Type: GrantFiled: June 23, 2010Date of Patent: February 2, 2016Assignee: Texas Tech University SystemInventors: Afzal A. Siddiqui, Gul Ahmad, Weidong Zhang
-
Patent number: 9193778Abstract: The present invention relates generally to the field of immunology. More particularly, aspects of the invention concern the discovery of several T cell receptors (TCRs) that are specific for an immunodominant CTL epitope of hepatitis C virus (HCV). Embodiments include TCRs, DNAs encoding TCRs, methods of making TCRs, and methods of using TCRs to treat, prevent or inhibit hepatitis C virus (HCV) proliferation.Type: GrantFiled: November 23, 2010Date of Patent: November 24, 2015Assignee: Tripep ABInventor: Margaret Sällberg Chen
-
Patent number: 9187330Abstract: Devices, compositions, and methods are described which provide a tubular nanostructure targeted to a lipid bilayer membrane. The targeted tubular nanostructure can have a surface region configured to pass through a lipid bilayer membrane of a cell, a hydrophobic surface region flanked by two hydrophilic surface regions configured to form a pore in a lipid bilayer membrane of a cellular organelle, and at least one ligand configured to bind one or more cognates on the lipid bilayer membrane of the cellular organelle. The target cell can be, for example, a tumor cell, an infected cell, or a diseased cell in a subject. The tubular nanostructure can form a pore in the lipid bilayer membrane of the cellular organelle, e.g., mitochondria, which can permit transit or translocation of at least one compound across the membrane and cause cell death of the target cell.Type: GrantFiled: September 15, 2008Date of Patent: November 17, 2015Assignee: The Invention Science Fund I, LLCInventors: Mahalaxmi Gita Bangera, Ed Harlow, Roderick A. Hyde, Muriel Y. Ishikawa, Edward K. Y. Jung, Eric C. Leuthardt, Nathan P. Myhrvold, Dennis J. Rivet, Elizabeth A. Sweeney, Clarence T. Tegreene, Lowell L. Wood, Jr., Victoria Y. H. Wood
-
Patent number: 9180149Abstract: The present invention concerns methods and compositions for the treatment of cancer and cancer cells using intravascular administration of a vaccinia virus. In some embodiments, methods and compositions involve a replicative vaccinia virus that encodes GM-CSF.Type: GrantFiled: September 7, 2006Date of Patent: November 10, 2015Assignee: SILLAJEN BIOTHERAPEUTICS, INC.Inventor: David Kirn
-
Patent number: 9149024Abstract: Described are methods and compositions for increasing islet-1 (Isl1) activity (e.g., biological activity) and or expression (e.g., transcription and/or translation) in a biological cell and or in a subject.Type: GrantFiled: June 22, 2010Date of Patent: October 6, 2015Assignee: Massachusetts Eye & Ear InfirmaryInventors: Mingqian Huang, Albena Kantardzhieva, Zheng-Yi Chen
-
Patent number: 9145447Abstract: The present disclosure provides an isolated nucleic acid sequence encoding a monomeric photoconvertible fluorescent protein, and fragments and derivatives thereof. Also provided is a method for engineering the nucleic acid sequence, a vector comprising the nucleic acid sequence, a host cell comprising the vector, and use of the vector in a method for expressing the nucleic acid sequence. The present disclosure further provides an isolated nucleic acid, or mimetic or complement thereof, that hybridizes under stringent conditions to the nucleic acid sequence. Additionally, the present provides a monomeric photoconvertible fluorescent protein encoded by the nucleic acid sequence, as well as derivatives, fragments, and homologues thereof. Also provided is an antibody that specifically binds to the photoconvertible fluorescent protein.Type: GrantFiled: December 3, 2010Date of Patent: September 29, 2015Assignees: Allele Biotechnology & Pharmaceuticals, Inc., University of Alberta, TEC EdmontonInventors: Jiwu Wang, Robert Earl Campbell, Hiofan Hoi, Nathan Christopher Shaner
-
Patent number: 9125906Abstract: Compositions and methods of using cells derived from umbilical cord tissue, to stimulate and support angiogenesis, to improve blood flow, to regenerate, repair, and improve skeletal muscle damaged by a peripheral ischemic event, and to protect skeletal muscle from ischemic damage in peripheral vascular disease patients are disclosed. In particular, methods of treating a patient having a peripheral vascular disease with umbilical derived cells and fibrin glue are disclosed.Type: GrantFiled: August 10, 2011Date of Patent: September 8, 2015Assignee: DePuy Synthes Products, Inc.Inventors: Charito S. Buensuceso, Anthony J. Kihm, Sridevi Dhanaraj, Roee Atlas, Israel Nur, Roberto Meidler, Liliana Bar
-
Patent number: 9115238Abstract: A cell culture microcarrier includes a polymer formed from copolymerization of a mixture including (i) an uncharged hydrophilic unsaturated monomer having a hydroxyl group; (ii) a hydrophilic carboxylic acid containing unsaturated monomer; and (iii) a hydrophilic multifunctional unsaturated monomer. The microcarrier may further include a polypeptide, such as a polypeptide that promotes cell adhesion, conjugated to the surface of the microcarrier; e.g. via the carboxyl group from the hydrophilic carboxylic acid containing unsaturated monomer. Some of the microcarriers support attachment of human embryonic stem cells.Type: GrantFiled: May 27, 2010Date of Patent: August 25, 2015Assignee: Corning IncorporatedInventors: Sophie Deshayes, David Henry, Martial Hervy
-
Patent number: 9115354Abstract: This disclosure relates to the discovery and isolation of the entire cluster of genes encoding R-type high molecular weight bacteriocins that specifically kill Clostridium difficile bacteria, dangerous pathogens. Also disclosed are methods of producing the R-type bacteriocins in innocuous aerobic producer cells. Disclosed also are small, non-ORF1374 receptor binding domains (RBDs), which are incorporated into diffocins to form engineered or variant diffocins having altered killing spectra. Variant diffocins provided herein may include a heterologous RBD and its cognate base plate attachment region (BPAR), or a fused BPAR. This invention offers a potent bactericidal agent with increased thermal and pH stability, and methods for producing it, in order to kill selectively C. difficile bacteria in the environment of the gastrointestinal tract where they can cause great harm and even death of the infected patient or farm animal.Type: GrantFiled: March 14, 2013Date of Patent: August 25, 2015Assignee: AvidBiotics Corp.Inventors: Gregory R. Govoni, Dana M. Gebhart, Dean M. Scholl
-
Patent number: 9109211Abstract: The present invention relates to polypeptides having phytase activity. These polypeptides have an amino acid sequence which has at least 70% identity to either of three phytases derived from the bacterium Buttiauxella, and which comprises at least one of the following amino acids at the position indicated: 119N, 120L, and/or 121E. These phytases have an improved specific activity. Additional specific amino acid substitutions are also disclosed which characterize and distinguish additional phytases of the invention having improved properties such as temperature and/or pH stability, pH activity profile, temperature activity profile, substrate profile, improved performance in animal feed in vitro or in vivo. The invention also relates to isolated polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides.Type: GrantFiled: July 19, 2013Date of Patent: August 18, 2015Assignee: Novozymes A/SInventors: Carsten Sjoeholm, Soeren Flensted Lassen, Lars Kobberoee Skov, Leonardo De Maria
-
Patent number: 9109087Abstract: A branched polyamine comprises about 8 to about 12 backbone tertiary amine groups, about 18 to about 24 backbone secondary amine groups, a positive number n? greater than 0 of backbone terminating primary amine groups, and a positive number q greater than 0 of backbone terminating carbamate groups of formula (2): wherein (n?+q) is a number equal to about 8 to about 12, the starred bond of formula (2) is linked to a backbone nitrogen of the branched polyamine, L? is a divalent linking group comprising 3 to 30 carbons, and q/(n?+q)×100% equals about 9% to about 40%.Type: GrantFiled: September 13, 2012Date of Patent: August 18, 2015Assignees: International Business Machines Corporation, Agency For Science, Technology And ResearchInventors: Wei Cheng, Daniel J. Coady, Amanda C. Engler, James L. Hedrick, Pei Yun Teo, Chuan Yang, Yi Yan Yang
-
Patent number: 9101658Abstract: Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.Type: GrantFiled: May 14, 2012Date of Patent: August 11, 2015Assignee: THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITYInventors: Christopher H. Contag, Stephen Thorne
-
Patent number: 9102949Abstract: The invention in some aspects relates to recombinant adeno-associated viruses useful for targeting transgenes to CNS tissue, and compositions comprising the same, and methods of use thereof. In some aspects, the invention provides methods and compositions for treating CNS-related disorders.Type: GrantFiled: April 22, 2011Date of Patent: August 11, 2015Assignee: University of MassachusettsInventors: Guangping Gao, Hongwei Zhang, Hongyan Wang, Zuoshang Xu